CA
DNA icon

Centerpoint Advisors’s Ginkgo Bioworks DNA Stock Holding History

Centerpoint Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000
Closed -$8K – 461
2024
Q3 		$8K Hold
1,000
– – ﹤0.01% 370
2024
Q2 		$13K Hold
1,000
– – ﹤0.01% 325
2024
Q1 		$46K Hold
1,000
– – 0.02% 176
2023
Q4 		$68K Hold
1,000
– – 0.03% 134
2023
Q3 		$72K Hold
1,000
– – 0.03% 136
2023
Q2 		$74K Hold
1,000
– – 0.03% 139
2023
Q1 		$53K Hold
1,000
– – 0.02% 154
2022
Q4 		$68K Buy
+1,000
New +$92K 0.03% 128

Other funds holding DNA

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Centerpoint Advisors's DNA Position: Q4 2024 in Review

Centerpoint Advisors sold out of Ginkgo Bioworks (DNA) in Q4 2024, closing a stake of 1,000 shares — an estimated $8K sold.

Centerpoint Advisors first reported a position in DNA in Q4 2022 and held it in 8 quarters. The position peaked at $74K in Q2 2023. 166 funds tracked by Wall St. Rank hold DNA as of Q4 2024.

  • Centerpoint Advisors reported no remaining Ginkgo Bioworks position as of Q4 2024 after selling out during the quarter.
  • Centerpoint Advisors sold 1,000 Ginkgo Bioworks shares in Q4 2024, an estimated $8K.
  • Centerpoint Advisors first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 8 quarters.
  • Centerpoint Advisors's Ginkgo Bioworks position peaked at $74K in Q2 2023.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2024.

Based on Centerpoint Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.